Previous close | 2.6100 |
Open | 2.6100 |
Bid | 2.4000 |
Ask | 2.9000 |
Strike | 4.00 |
Expiry date | 2024-10-18 |
Day's range | 2.6100 - 2.6100 |
Contract range | N/A |
Volume | |
Open interest | 30 |
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.